Related Experiment Videos
Cardiovascular risk factors. Which ones can and should be remedied?
1Rush Medical College of Rush University, Chicago.
Insights
Controlling risk factors can significantly reduce the incidence of coronary artery disease (CAD). Physician
Area of Science:
- Cardiology
- Preventive Medicine
- Epidemiology
Background:
- Coronary artery disease (CAD) is a common multifactorial condition.
- Risk factor control is crucial for reducing CAD incidence.
- Epidemiologic studies and intervention trials support this approach.
Purpose of the Study:
- To summarize the evidence supporting risk factor modification in CAD.
- To emphasize the role of physicians in applying trial data to individual patient care.
Main Methods:
- Review of large epidemiologic studies.
- Analysis of randomized intervention trials.
- Synthesis of findings from multiple risk factor intervention trials.
Main Results:
- Strong evidence supports the reduction of CAD incidence through risk factor control.
- Specific therapies targeting risk factors have been validated in trials.
- Individual patient benefit is derived from established intervention successes.
Conclusions:
- Coronary artery disease incidence can be reduced and potentially prevented.
- Physicians play a vital role in translating clinical trial evidence into personalized patient management.
- Effective management of CAD relies on understanding and controlling its multifactorial nature.
Abstract:
Coronary artery disease (CAD) is probably the most common example of a multifactorial disease that can be reduced in incidence (if not prevented in some cases) by appropriate attention to and control of risk factors. This conclusion is supported by large epidemiologic studies, confirmed by randomized intervention trials in which a putative risk factor is attacked with specific therapy, and put into context by the results of multiple risk factor intervention trials. The job of the physician is to take the pieces of scientific data regarding CAD and extrapolate them, if appropriate, to individual patients, who presumably will benefit from all the hard work their predecessors in clinical trials went through to prove that the intervention was successful.